Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in patients with hypertension and left ventricular hypertrophy? The LIFE study

被引：0
|
作者：
Ibsen, H
Olsen, MH
Wachtell, K
Borch-Johnsen, K
Lindholm, L
Dahlof, B
Snapinn, S
机构：
[1] Glostrup Cty Hosp, Glostrup, Denmark
[2] Steno Diabet Ctr, DK-2820 Gentofte, Denmark
[3] Umea Univ, Umea, Sweden
[4] Univ Gothenburg, Gothenburg, Sweden
[5] Merck, W Point, PA USA
来源：
JOURNAL OF HYPERTENSION | 2003年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R6 [外科学];
学科分类号：
1002 ; 100210 ;
摘要：
引用
收藏
页码：S68 / S68
页数：1
相关论文
共 50 条
  • [21] The effect of losartan versus atenolol on hemostasis and fibrinolysis in hypertensive patients with left ventricular hypertrophy: A LIFE substudy
    Boman, KO
    Olsen, MH
    Wachtell, K
    Olofsson, M
    Ibsen, H
    Dige-Petersen, H
    Nilsson, TK
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 43 (05) : 482A - 482A
  • [22] Losartan for LIFE in hypertension with left ventricular hypertrophy?
    Doggrell, SA
    EXPERT OPINION ON PHARMACOTHERAPY, 2003, 4 (01) : 115 - 118
  • [23] Losartan benefits over atenolol in nonsmoking hypertensive patients with left ventricular hypertrophy:: The LIFE study
    Reims, HM
    Kjeldsen, SE
    Devereux, RB
    Oparil, S
    Julius, S
    Brady, WE
    Dahlöf, B
    AMERICAN JOURNAL OF HYPERTENSION, 2004, 17 (05) : 186A - 186A
  • [24] Does losartan reduce the incidence of revascularizations in patients with hypertension and electrocardiographic left ventricular hypertrophy?: The LIFE Study
    Olsen, MH
    Wachtell, K
    Dahlöf, B
    Devereux, RB
    Ibsen, H
    Kjeldsen, SE
    Lindholm, L
    Nieminen, MS
    EUROPEAN HEART JOURNAL, 2004, 25 : 328 - 328
  • [25] Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy:: The LIFE study
    Wachtell, K
    Ibsen, H
    Olsen, MH
    Borch-Johnsen, K
    Lindholm, LH
    Mogensen, CE
    Dahlöf, B
    Devereux, RB
    Beevers, G
    de Faire, U
    Fyhrquist, F
    Julius, S
    Kjeldsen, SE
    Kristianson, K
    Lederballe-Pedersen, O
    Nieminen, MS
    Okin, PM
    Omvik, P
    Oparil, S
    Wedel, H
    Snapinn, SM
    Aurup, P
    ANNALS OF INTERNAL MEDICINE, 2003, 139 (11) : 901 - 906
  • [26] Regression of electrocardiographic left ventricular hypertrophy by losartan vs atenolol: The LIFE study
    Okin, PM
    Jern, S
    Kjeldsen, SE
    Julius, S
    Nieminen, MS
    Snapinn, S
    Harris, KE
    Aurup, P
    Edelman, JM
    CIRCULATION, 2002, 106 (19) : 477 - 477
  • [27] Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy:: The LIFE Study
    Ibsen, H
    Wachtell, K
    Olsen, MH
    Borch-Johnsen, K
    Lindholm, LH
    Mogensen, CE
    Dahlöf, B
    KIDNEY INTERNATIONAL, 2004, 66 : S56 - S58
  • [28] Losartan-based versus atenolol-based therapy in patients with hypertension and left ventricular hypertrophy: An economic evaluation of the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study for Germany
    Krobot, K. J.
    Carides, G. W.
    Wagner, A.
    Burke, T. A.
    VALUE IN HEALTH, 2006, 9 (06) : A353 - A353
  • [29] Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy
    Dahlof, B
    Zanchetti, A
    Diez, J
    Nicholls, MG
    Yu, CM
    Barrios, V
    Aurup, P
    Smith, RD
    Johansson, M
    JOURNAL OF HYPERTENSION, 2002, 20 (09) : 1855 - 1864
  • [30] Impact of age on left ventricular hypertrophy regression during antihypertensive treatment with losartan or atenolol (the LIFE study)
    Gerdts, E
    Roman, MJ
    Palmieri, V
    Wachtell, K
    Smith, G
    Nieminen, MS
    Dahlöf, B
    Devereux, RB
    JOURNAL OF HUMAN HYPERTENSION, 2004, 18 (06) : 417 - 422
12345